Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

FDA: Class I Recall for Cook Medical’s CrossCath Support Catheters

L.A. McKeown

December 17, 2019

News Features

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

L.A. McKeown

December 12, 2019

News Daily News

Sex-Specific Troponin Cutoffs Find Many More Women With Myocardial Injury

Todd Neale

October 14, 2019

News Featured Fellow

Shane Prejean, MD

Yael L. Maxwell

August 20, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

Yael L. Maxwell

June 18, 2019

News Daily News

The Perils of Perusing: New Research Cautions Against Relying Solely on RCT Abstracts

Caitlin E. Cox

May 07, 2019

News Industry News

Cook Medical Provides Patient-Level Paclitaxel Data From Randomised Control Trial

April 19, 2019

News Featured Fellow

Philipp Wiesner, MD

Yael L. Maxwell

April 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

CME

Advertisement

FDA: Class I Recall for Cook Medical’s CrossCath Support Catheters

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

Sex-Specific Troponin Cutoffs Find Many More Women With Myocardial Injury

Shane Prejean, MD

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

The Perils of Perusing: New Research Cautions Against Relying Solely on RCT Abstracts

Cook Medical Provides Patient-Level Paclitaxel Data From Randomised Control Trial

Philipp Wiesner, MD

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Updates on TAVR in Low-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content